Skip to main content
    V

    Volitionrx Ltd (VNRX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • AMEX

    $0.18
    -0.02 (-7.66%)

    Market Cap: $7.21M

    Last updated: Nov 17, 2026 at 4:30 PM ET

    Volitionrx Ltd (VNRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Volitionrx (VNRX) has a market cap of $7.21M and an enterprise value of $12.78M. It kept -700.48% of revenue as net income over the last 12 months. Revenue grew 133.54% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 77.25% above the market cap, as debt exceeds cash.

    Market Cap$7.21M
    Enterprise Value$12.78M
    Latest price (Nov 17, 2026)$0.18

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 164.36% in the quarter ended Sep 30, 2026.

    Shares Outstanding36.08M
    Shares Change (QoQ)+164.36%

    Valuation Ratios

    The price to sales ratio is 1.9x. Its year-end P/S ranged from 19.4x to 440.7x from 2022 to 2025.

    P/S Ratio1.9x
    Forward P/S2.6x

    Price Statistics

    The stock is down 97.21% over 52 weeks and trades 18.18% below its 50-day average.

    Beta (1Y)1.46
    52-Week Change-97.21%
    1-Month Change+6.16%
    3-Month Change-62.20%
    6-Month Change-92.15%
    5-Year Change-99.71%
    10-Year Change-99.78%
    Total Return (1Y)-97.21%
    Total Return (3Y CAGR)-76.89%
    Total Return (5Y CAGR)-70.22%
    Max Drawdown (1Y)-97.66%
    Max Drawdown (3Y)-99.30%
    Sharpe Ratio (1Y)-3.42
    Correlation with SPY (1Y)0.19
    50-Day Average$0.22
    200-Day Average$1.84
    52-Week Range$0.16 to $7.73
    RSI (14 Days)43.9
    Average Volume (20 Days)4.08M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.33x current liabilities.

    Current Ratio0.33x
    Quick Ratio0.33x
    Interest Coverage-3.96x

    Returns and Efficiency

    Return on invested capital is 83.67% over the last 12 months.

    Return on Assets (ROA)-334.96%
    Return on Invested Capital (ROIC)83.67%
    Asset Turnover0.50x
    Receivables Turnover14.98x

    Scores

    VNRX has an Altman Z-Score of -62.06, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-62.06
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $3.44M over the last 12 months.

    Revenue$3.44M
    Revenue Growth (YoY)+133.54%
    Gross Profit$3.44M
    Operating Income-$17.66M
    Pretax Income-$24.13M
    Net Income-$24.13M
    EBITDA-$16.11M
    EBIT-$19.27M
    Reported EPS (TTM)-$2.00

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$2.36M
    Total Debt$7.93M
    Net Debt$5.57M
    Net Debt Per Share$0.15
    Working Capital-$6.66M
    Shareholder Equity-$26.12M
    Tangible Book Value-$26.41M
    Total Assets$7.20M
    Total Liabilities$34.70M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $68.91K of capital spending, operating cash flow left -$20.59M of free cash flow.

    Operating Cash Flow-$20.52M
    Capital Expenditures$68.91K
    Free Cash Flow-$20.59M
    FCF Per Share-$0.68
    Depreciation and Amortization$3.16M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -512.59%.

    Gross Margin100.00%
    Operating Margin-512.59%
    Pretax Margin-700.54%
    Net Margin-700.48%
    EBITDA Margin-467.59%
    EBIT Margin-559.29%
    FCF Margin-597.63%

    Growth

    Revenue grew 77.98% a year over 3 years.

    Revenue Growth (3Y CAGR)+77.98%
    Revenue Growth (5Y CAGR)+129.95%

    Revenue and profit by year

    Dividends and Yields

    VNRX does not pay a dividend. Its free cash flow yield is -309.23%.

    FCF Yield-309.23%
    Buyback Yield-364.24%
    Shareholder Yield-364.24%

    Stock Splits

    The last split was a 1-for-20 reverse split on Apr 28, 2026.

    Last Split DateApr 28, 2026
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 7 similar companies, VNRX has the 2nd highest P/S.

    P/S Ratio1.9x vs 0.6x median
    ROIC83.67% vs -147.05% median
    Revenue Growth (Trailing 4 Quarters, YoY)+133.54% vs +7.79% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 131.71% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+131.71%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About VNRX

    What is VNRX's market cap?

    Volitionrx has a market cap of $7.21M. Its enterprise value, which adds debt and subtracts cash, is $12.78M.

    How many shares of VNRX are outstanding?

    Volitionrx has 36.08M shares outstanding.

    Does VNRX pay a dividend?

    No. Volitionrx does not pay a dividend.

    How much debt does VNRX have?

    Volitionrx has $7.93M of total debt and $2.36M of cash and equivalents, a net debt position of $5.57M.